Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,910 signal articles · 107 in last 24h · 135,599 total before filter · latest 54m ago
107last 24h
1098last 7d
180● bullish (7d)
143● bearish (7d)
209publishers
AllMacro303Earnings358M&A79Regulatory24Product11Analyst14
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Jim Cramer Explains Why He Recommends Buying KLA (KLAC) Stock in Small Doses
Insider Monkey1d agobullish
Jim Cramer Explains Why He Recommends Buying KLA (KLAC) Stock in Small Doses

Noting that long-held KLA Corporation (NASDAQ:KLAC) shares had pulled back significantly after peaking past $300 in June, a caller on the September 1 episode of Mad Money asked if it is a buy, hold, or sell. In response, Jim Cramer said: I think it’s a great company. It is up 40% for the year. Its […]

Jim Cramer Calls CrowdStrike (CRWD) a Cybersecurity Heavy Hitter
Insider Monkey1d agoneutral
Jim Cramer Calls CrowdStrike (CRWD) a Cybersecurity Heavy Hitter

On the September 1 episode of Mad Money, Jim Cramer called CrowdStrike Holdings, Inc. (NASDAQ:CRWD) a “heavy hitter” in cybersecurity and highlighted its Fal.Con conference in Las Vegas, as he said: Listen, this is really important. Today was brutal for all things tech because these stocks tend to sell off horribly when hostilities with Iran […]

RTX (RTX) Stock Looks Below Fair Value On Cash Flow, Near Fair Value On Earnings
Simply Wall St.1d agoneutral
RTX (RTX) Stock Looks Below Fair Value On Cash Flow, Near Fair Value On Earnings

RTX stock has delivered a very strong 5 year run, yet current valuation checks send a mixed message, with a Discounted Cash Flow (DCF) view pointing to some undervaluation while market multiples look closer to fair. Recent contract wins in defense and aerospace add fresh context to that gap between price and intrinsic value estimates. Over the past 5 years RTX has returned 169.7%, which puts fresh focus on whether the current share price already embeds most of the good news. RTX’s recent...

Has Eos Energy Enterprises (EOSE) Fallen Far Enough To Justify Its Premium?
Simply Wall St.1d agobearish
Has Eos Energy Enterprises (EOSE) Fallen Far Enough To Justify Its Premium?

Eos Energy Enterprises stock has delivered a steep 73.0% decline over the past five years, while current market multiples screen the shares as overvalued and the broader checks point to only a mixed picture on value. For investors looking at the recent news on new projects, manufacturing changes and leadership moves, the question is how much of that is already reflected in the current share price. The share price has fallen 73.0% over five years, which means many long term holders are...

Why Axcelis Technologies (ACLS) Is Back On Investor Radars
Simply Wall St.1d agoneutral
Why Axcelis Technologies (ACLS) Is Back On Investor Radars

Why Axcelis Technologies Is Back On Investor Radars Axcelis Technologies (ACLS) recently announced plans to join upcoming investor conferences, including the Citi 2026 Global TMT Conference and the B. Riley Securities Consumer & TMT Conference, which has put fresh attention on the stock. The recent conference announcements come after a mixed price pattern for Axcelis Technologies, with the share price up 28.62% year to date but down 31.57% over 90 days. The 1-year total shareholder return of...

What Does Eli Lilly (LLY) Gain From Its $2.88 Billion Immunology Deal?
Simply Wall St.1d agoneutral
What Does Eli Lilly (LLY) Gain From Its $2.88 Billion Immunology Deal?

Eli Lilly (NYSE: LLY) agreed to acquire Merida Biosciences in a deal valued at up to US$2.88b to expand its immunology pipeline. The transaction brings Merida's platform for selectively degrading pathogenic autoantibodies while maintaining normal immune function into Lilly's portfolio. Merida's lead autoimmune and allergy candidate is in Phase 1 and is expected to support Lilly's move beyond its established focus on diabetes and obesity therapies. For readers looking to explore more...

What DraftKings (DKNG)'s New $700 Million Term Loan and Larger Credit Line Means For Shareholders
Simply Wall St.1d agoneutral
What DraftKings (DKNG)'s New $700 Million Term Loan and Larger Credit Line Means For Shareholders

In August 2026, DraftKings amended its credit agreement to add a US$700 million Term B loan due 2033 and expand its revolving credit facility to US$750 million maturing in 2031, largely to refinance existing 0% convertible notes and fund general corporate purposes. This refinancing shifts part of DraftKings’ capital structure from zero‑coupon convertible debt toward secured term loans and a larger credit line, potentially affecting future interest costs and financial flexibility. We’ll now...

Bloom Energy Stock Surges Thursday: What's Going On?
Benzinga1d agobullish
Bloom Energy Stock Surges Thursday: What's Going On?

Shares of Bloom Energy Corp (NYSE:BE) are rallying Thursday afternoon, trading higher after market sentiment received a major boost from falling U.S. Treasury yields. The clean energy technology provider is gaining momentum alongside capital-intensive growth equities following key commentary from Federal Reserve Governor Christopher Waller. Here’s what investors need to know. Bloom Energy stock is showing exceptional strength. What’s driving BE stock higher? Fed’s Waller Hints at Interest Rate P